Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (Q38802138)
Jump to navigation
Jump to search
scientific article published on 5 May 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study |
scientific article published on 5 May 2017 |
Statements
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. (English)
1 reference
K T Flaherty
H Gogas
F de Braud
J Larkin
T Jouary
A Hauschild
C Lebbe
M MandalÃ
M Millward
J B A G Haanen
J Hansson
V Ferraresi
P Mohr
V Probachai
D Schadendorf
P Nathan
A Ribas
M A Davies
S R Lane
J J Legos
B Mookerjee
1 July 2017
1 reference